		4:3:1	:3:3:1		4:3:1:3 [‡] :3:1:4				4+ DTaP/DTP/DT				3+ Polio vaccine						ИMR		1+ VAR			
	U.S.	± CI	Idaho	± CI	U.S.	± CI	ldaho	± CI	U.S.	± CI	Idaho	± CI	U.S.	± CI	Idaho	± CI	U.S.	± CI	ldaho	± CI	U.S.	± CI	Idaho	± Cl
2006 n=222	76.9	1.0	68.2	6.9					85.2	0.9	82.4	5.8	92.8	0.6	92.2	3.9	92.3	0.6	88.0	4.8	89.2	0.7	77.4	1 .
2007	/0.9	1.0	08.2	0.9		1			80.2	0.9	82.4	5.8	92.8	0.0	92.2	3.9	92.3	U.0	88.0	4.8	89.2	0.7	11.4	6.
n=183	77.4	1.1	65.7	7.2	66.5	1.3	52.9	7.6	84.5	0.9	77.2	6.3	92.6	0.7	87.6	4.9	92.3	0.7	86.1	5.2	90.0	0.7	75.5	6.4
2008																								
1=282	76.1	1.1	60.4	6.8	68.4	1.2	54.2	6.7	84.6	1.0	77.6	5.9	93.6	0.6	91.8	3.7	92.1	0.7	86.1	5.4	90.7	0.7	80.7	5.8
2009																								i
1=207	69.9	1.2	51.7	7.7	44.3	1.4	33.6	7.2	83.9	1.0	84.0	5.5	92.8	0.7	94.7	3.5	90.0	0.8	88.1	4.8	89.6	0.8	84.1	5.7
2010																								i .
1=271	74.9	1.1	61.2	6.7	56.6	1.3	42.6	6.8	84.4	1.0	77.9	5.7	93.3	0.7	89.2	4.7	91.5	0.7	87.2	5.0	90.4	0.8	83.7	5.1
2011 n=282	77.0	1.1	68.8	7.6	68.5	1.3	57.1	8.4	84.6	1.0	79.0	6.6	93.9	0.6	94.5	3.1	91.6	0.8	89.5	4.8	90.8	0.7	86.0	5.6
2012.	11.0	1.1	00.0	7.0	00.5	1.5	37.1	0.4	04.0	1.0	77.0	0.0	73.7	0.0	74.5	J.1	71.0	0.0	07.5	4.0	70.0	0.7	00.0	J.(
1=289	71.9	1.4	64.5	8.1	68.4	1.4	63.0	8.2	82.5	1.2	76.6	6.7	92.8	0.7	92.6	3.9	90.8	0.8	93.3	3.6	90.2	0.1	90.3	4.3
2013																								
1=233	74.0	1.4	71.6	6.8	70.4	1.5	70.2	6.9	83.1	1.3	84.2	5.3	92.7	1.0	92.6	3.7	91.9	0.9	91.1	4.3	91.2	0.9	87.9	4.8
2014																								ı
1=235	74.6	1.4	67.2	8.0	71.6	1.5	65.9	8.0	84.2	1.2	77.7	7.2	93.3	8.0	93.1	4.3	91.5	0.9	89.7	5.1	91.0	0.9	90.0	5.0
2015 n=209	75.1	1.3	73.7	6.6	72.2	1.4	71.6	6.8	84.6	1.1	81.0	5.9	93.7	0.6	88.9	4.9	91.9	0.8	91.2	4.0	91.8	0.8	88.5	4.6
1016	75.1	1.3	13.1	0.0	12.2	1.4	71.0	0.0	04.0	1.1	01.0	3.7	73.7	0.0	00.7	4.7	71.7	0.0	71.2	4.0	71.0	0.0	00.3	4.0
1=225	73.8	1.5	75.2	6.6	70.7	1.5	73.9	6.7	83.4	1.3	83.9	5.7	91.9	1.0	91.1	4.4	91.1	1.0	88.6	4.9	90.6	1.0	86.9	5.2
2017	10.0																							
n=198	73.2	1.4	72.5	7.3	70.4	1.5	69.2	7.6	83.2	1.2	82.3	6.4	92.7	0.8	90.8	4.8	91.5	0.9	92.2	4.4	91.0	0.9	90.1	4.8
	HIB-FS							HIB-PS				4+ PCV					A vaccine		Rotavirus					
	U.S.	± CI	Idaho	± CI	U.S.	± CI	ldaho	± CI	U.S.	± CI	Idaho	± CI	U.S.	± CI	Idaho	± CI	U.S.	± CI	ldaho	± CI	U.S.	± CI	Idaho	± CI
006																								
007					93.4	0.6	91.3	4.2					68.4	1.1	72.1	6.5								
102					02./	0.7	0/ 2	F 1					75.0	1.2	,,,	7.0	17.0	1.1	21.5					

	HIB-FS					3+ H	IB vaccine		HIB-PS					4+	PCV			2+ Hep.	A vaccine		Rotavirus				
	U.S.	± CI	ldaho	± CI	U.S.	± CI	ldaho	± CI	U.S.	± CI	Idaho	± CI	U.S.	± CI	Idaho	± CI	U.S.	± CI	ldaho	± CI	U.S.	± CI	Idaho	± CI	
2006																									
n=222					93	.4 (0.6 91.3	4.2					68.4	1.1	72.1	6.5			,						
2007 n=183													75.0				47.0								
					92	.6 ().7 86.3	5.1					75.3	1.2	66.6	7.2	17.8	1.1	21.5	6.4					
2008 n=282					90	0).7 77.6	3.4					80.1	1.1	74.8	6.3	40.4	1.2	38.6	6.5					
2009	-				70	.,	77.0	J.1					00.1	- 1.1	74.0	0.0	40.4	1.2	30.0	0.5					
n=207					86	.6	.0 64.1	7.5	92.1	0.8	90.	9 4.5	80.4	1.1	82.5	6.0	46.6	1.4	37.3	7.5	43.9	1.4	30.	3 7.2	
2010																									
n=271	66.8	1.3	53.	.3 6.	9 90	.4 ().9 77.7	6.2	92.2	0.8	82.	5.9	83.3	1.0	79.7	5.5	49.7	1.4	44.2	6.8	59.2	1.4	50.	4 6.9	
2011																									
n=282	80.4	1.1	75.	.0 7.	3 94	.0 ().6 94.7	3.1	94.2	0.6	94.	3.1	84.4	1.0	84.1	5.7	52.2	1.4	45.2	2 8.6	67.3	1.3	62.0	0 8.2	
2012,	l			_		_																		_	
n=289 2013	80.9	1.2	77.	.3 7.	6 93	.0 ().7 92.3	3.9	93.3	0.7	92.	7 3.9	81.9	1.1	83.9	4.8	53.0	1.1	52.8	8.6	68.6	1.4	68.	2 7.1	
n=233	82.0	1.3	80.	.0 5.	9 92	.8	0.9 91.2	4.3	93.3	0.9	94.	7 3.1	82.0	1.3	87.3	4.6	54.7	1.6	60.7	7.3	72.6	1.5	74.0	6 6.4	
2014																									
n=235	82.0	1.3	80.	.4 6.	5 92	.6	0.8 93.5	4.1	92.8	0.9	94.	3.6	82.9	1.3	83.6	6.2	57.5	1.6	59.4	8.2	71.7	1.6	79.	5 6.	
2015																									
n=209	82.7	1.1	81.	.2 5.	9 92	.4 ().7 88.3	4.9	93.7	0.7	90.	3 4.4	84.1	1.1	84.4	5.5	59.6	1.5	58.8	7.3	73.2	1.4	74.	5 6.6	
2016												1					1								
n=225	81.8	1.3	79.	.9 6.	1 91	.6 ().9 88.3	4.9	92.8	0.9	90.:	2 4.5	81.8	1.3	83.5	5.8	60.6	1.6	67.1	1 7.5	74.1	1.5	80.:	2 6.0	
2017 n=198	80.7	1.3	83.	.8 6.	0 91	9	0.9 92.0	4.4	92.8	0.8	92.	4.4	82.4	1.3	82.4	6.3	59.7	1.6	66.0	7.6	73.2	1.6	78.	5 6.	

		3+ Hep E	3 vaccine		1+	Hep B vac	cine, 0-1 c	lay	1+	Hep B vac	cine, 0-2 c	lay	1+ Hep B vaccine, 0-3 day					
	U.S.	± CI	ldaho	± CI	U.S.	± CI	ldaho	± CI	U.S.	± CI	ldaho	± CI	U.S.	± CI	Idaho	± CI		
2006																		
n=222	93.3	0.6	92.9	3.5	42.8	1.1	42.3	7.2	48.5	1.1	47.5	7.3	50.1	1.1	48.6	7.3		
2007																		
n=183	92.7	0.7	88.8	4.7	45.3	1.3	54.5	7.7	50.6	1.3	58.8	7.6	52.4	1.3	59.7	7.5		
2008																		
n=282	93.5	0.7	93.3	3.4	47.2	1.3	59.8	6.7	53.7	1.3	63.5	6.6	55.3	1.3	64.0	6.6		
2009																		
n=207	92.4	0.7	94.3	3.6	52.7	1.4	65.7	7.3	58.9	1.3	69.6	7.1	60.8	1.3	70.3	7.1		
2010																		
n=271	91.8	0.7	86.8	4.9	56.1	1.3	62.3	6.5	62.5	1.3	64.2	6.4	64.1	1.3	65.2	6.4		
2011																		
n=282	91.1	0.7	86.3	5.4	60.2	1.3	67.5	7.7	66.7	1.3	70.0	7.5	68.6	1.3	70.2	7.5		
2012,																		
n=289	89.0	0.9	87.7	5.0	63.2	1.4	68.3	7.9	70.0	1.4	70.0	7.8	71.6	1.4	70.1	7.8		
2013																		
n=233	90.8	1.0	90.7	4.3	65.0	1.5	68.2	6.8	72.3	1.5	72.3	6.6	74.2	1.4	72.7	6.5		
2014																		
n=235	91.6	0.9	95.1	3.5	64.0	1.6	71.8	7.7	70.8	1.6	74.5	7.5	72.4	1.5	75.4	7.4		
2015																		
n=209	92.6	0.7	89.8	4.6	63.9	1.5	66.4	7.1	70.8	1.4	68.6	7.0	72.4	1.4	69.8	6.9		
2016																		
n=225	90.5	1.1	89.4	4.7	63.4	1.6	63.8	8.0	69.6	1.6	68.1	7.7	71.1	1.6	68.3	7.7		
2017																		
n=198	91.4	0.9	90.7	4.7	65.7	1.6	73.6	7.1	72.0	1.6	74.7	7.0	73.6	1.6	75.6	6.9		

Full series Haemophilus influenzae type b (Hib) vaccine: 23 or 24 doses, depending on brand received Idaho data points in BOLD indicate a statistically significant change compared with the previous year, p=0.05 Blue cells indicate NIS did not collect data during that year CI - Confidence Interval

Glossary of Abbreviations and Terms

4:3:1:3:3:1 The series of 4 or more DTaP vaccinations, 3 or more polio vaccinations, 1 or more MMR vaccinations, 3 or more Hib vaccinations of any type, 3 or more hepatitis B vaccinations, and 1 or more Varicella vaccinations given at age 12 months or older

4:3:1:3‡:3:1:4 The series of 4 or more DTaP vaccinations, 3 or more polio vaccinations, 1 or more MMR vaccinations, 2 or 3 Hib vaccinations depending on brand received, 3 or more hepatitis B vaccinations,

1 or more Varicella vaccinations given at age 12 months or older, and 4 or more pneumococcal vaccinations

DTaP Diphtheria and tetanus toxoids and acellular pertussis vaccine

DTP Diphtheria and tetanus toxoids and pertussis vaccine

DT Diphtheria and tetanus toxoid vaccine

FT Full series

Hep A Hepatitis A

Hep B Hepatitis B

Hib Haemophilus influenzae type b


MMR Measles, mumps and rubella vaccine

NIS National Immunization Survey

PCV Pneumococal conjugate vaccine

PS Primary Series

VAR Varicella Vaccine



^{*} Refers to 4 or more doses of diphtheria and tetanus toxoids and pertussis vaccine, or diphtheria and tetanus toxoids (DTP/DT/DTaP), 3 or more doses of polio virus vaccine, 1 or more doses a measles-mumps-rubella (MMR) vaccine, 3 or more doses of Haemophilus influenzae type b (Hib) vaccine of any type, 3 or more doses of hepatitis B vaccine, and 1 or more doses of varicella vaccine

* Refers to a statistically significant change compared with the previous year, p=0.05

n=282

n=289

n=233

n=235

n=209

n=225

n=198


n=183

n=222

n=282


n=207


n=271





*Refers to 4 or more doses of diphtheria and tetanus toxoids and pertussis vaccine, or diphtheria and tetanus toxoids (DTP/DT/DTaP), 3 or more doses of polio virus vaccine, 1 or more doses of a measles-mumps-rubella vaccine (MMR), plus full series of Haemophilus influenzae type b (Hib), 3 or more doses of hepatitis B vaccine, 1 or more doses of varicella vaccine, and 4 or more doses of pneumococcal conjugate vaccine (PCV)


‡ Full series Haemophilus influenzae type b (Hib) vaccine: ≥3 or ≥4 doses, depending on brand received
















^{*} Refers to 3 or more doses of Haemophilus influenzae type b (Hib) vaccine * Refers to a statistically significant change compared with the previous year, p=0.05





^{*}Refers to primary series Haemophilus influenzae type b (Hib) vaccine: ≥2 or ≥3 doses, depending on brand received

¹⁵ This series sampling began in 2009

^{*} Refers to a statistically significant change compared with the previous year, p=0.05








^{*} Refers to ≥2 or ≥3 doses of rotavirus vaccine depending on brand received

 [§] This series sampling began in 2009
 § Refers to a statistically significant change compared with the previous year, p=0.05



2006

n=222

30%

20%

2008

n=282

2009

n=207

2010

n=271

2011

n=282

2012,

n=289

2013

n=233

2014

n=235

2015

n=209

2016

n=225

2017


n=198


2007

n=183


^{*} Refers to 3 or more doses of hepatitis B vaccine


[¥] Refers to a statistically significant change compared with the previous year, p=0.05





^{*} Refers to 1 or more doses of hepatitis B vaccine given between 0–1 day from birth





* Refers to 1 or more doses of hepatitis B vaccine given between 0–2 day from birth

